Design and synthesis of novel glycopeptides and glycolipids as immune potentiators

Abstract

Interest in development of vaccine adjuvant is being intensed and grown, because many of the new subunit vaccine candidates are lack of sufficient immunogenicity to be clinically use. Therefore, there is a major unmet need for a safe and efficacious adjuvant capable of boosting both cellular and humoral immunity. While exploring the novel plant based immunoadjuvants, it was found that many glycoconjugates such as saponins possess promising dose dependant immune potentiator ability as indicated by B-cell and T-cell proliferation and cytokine production. This evoked interest to develop these products as alternate plant based immune adjuvants for vaccines and screened for immune adjuvants activity. newlineImmunophenotyping studies revealed the potential cross talks between B and T cells that stimulate immune responses (Furman and Davis 2015). CD4+ and CD8+ cells expressions were observed in groups treated with MDPOMyr with JEV (Figure 1.18). However, no significant changes were observed in the CD4+ cells expression of MDPOMyr + JEV treated groups at 5 and 10 and#956;g whereas CD8+ expressions were dose dependent. B cells expressing CD19 population were observed in group treated with MDPOMyr + JEV at 50 and#956;g, with significant increase (Figure 1.18). Measurement of co-stimulatory molecules (CD40-CD40L and CD28-CD80/CD86) expression reveal the activation of APCs, naïve T cells and their differentiation and regulation of immune cells migration (Toussi and Massari 2014). Heterogeneous spleen cells stained with antibodies against CD40, CD40L, CD28, and CD86 revealed the MDPOMyr + JEV and MDP activating the co-stimulatory molecules in JEV treated groups (Figure 1.18). newlineTo determine the effect of MDPOMyr and MDP on T and B cell responses, ex vivo proliferation studies against JEV antigen, LPS, and Con-A were measured. Lymphoproliferative responses of treated groups were measured in comparison with naïve and antigen alone treated groups the results reveal proliferation of both T and B cells by MDPOMyr and MDP. However MDPOMyr treated groups